These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1754 related items for PubMed ID: 15754350

  • 1. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S, Agoulnik IU, Weigel NL.
    Prostate; 2005 Sep 01; 64(4):362-72. PubMed ID: 15754350
    [Abstract] [Full Text] [Related]

  • 2. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.
    Cancer Res; 2004 Oct 01; 64(19):7156-68. PubMed ID: 15466214
    [Abstract] [Full Text] [Related]

  • 3. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
    Zhao XY, Peehl DM, Navone NM, Feldman D.
    Endocrinology; 2000 Jul 01; 141(7):2548-56. PubMed ID: 10875257
    [Abstract] [Full Text] [Related]

  • 4. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
    Zhao XY, Ly LH, Peehl DM, Feldman D.
    Endocrinology; 1997 Aug 01; 138(8):3290-8. PubMed ID: 9231780
    [Abstract] [Full Text] [Related]

  • 5. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA.
    Prostate; 2008 Jul 01; 68(10):1133-42. PubMed ID: 18454446
    [Abstract] [Full Text] [Related]

  • 6. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep 01; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 7. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
    Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H.
    Cancer Res; 1994 Oct 15; 54(20):5474-8. PubMed ID: 7522959
    [Abstract] [Full Text] [Related]

  • 8. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells.
    Bao BY, Hu YC, Ting HJ, Lee YF.
    Oncogene; 2004 Apr 22; 23(19):3350-60. PubMed ID: 15048085
    [Abstract] [Full Text] [Related]

  • 9. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
    Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G.
    Cancer Res; 1997 Mar 15; 57(6):1086-90. PubMed ID: 9067276
    [Abstract] [Full Text] [Related]

  • 10. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L, Giocanti N, Hennequin C, Favaudon V.
    Prostate; 2010 Mar 01; 70(4):401-11. PubMed ID: 19902473
    [Abstract] [Full Text] [Related]

  • 11. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.
    Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC.
    Oncogene; 2003 Aug 28; 22(36):5602-13. PubMed ID: 12944908
    [Abstract] [Full Text] [Related]

  • 12. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.
    Serda RE, Bisoffi M, Thompson TA, Ji M, Omdahl JL, Sillerud LO.
    Prostate; 2008 May 15; 68(7):773-83. PubMed ID: 18247401
    [Abstract] [Full Text] [Related]

  • 13. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A, Czwornog J, Gera L, Joshi S, Chatterton RT, Budunova I.
    Cancer Res; 2008 Jun 15; 68(12):4763-73. PubMed ID: 18559523
    [Abstract] [Full Text] [Related]

  • 14. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
    Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack PC, de Vere White RW.
    Prostate; 2007 Apr 01; 67(5):521-35. PubMed ID: 17252539
    [Abstract] [Full Text] [Related]

  • 15. Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase.
    Bai VU, Cifuentes E, Menon M, Barrack ER, Reddy GP.
    J Cell Physiol; 2005 Aug 01; 204(2):381-7. PubMed ID: 15887248
    [Abstract] [Full Text] [Related]

  • 16. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
    Gnanapragasam VJ, Robson CN, Neal DE, Leung HY.
    Oncogene; 2002 Aug 01; 21(33):5069-80. PubMed ID: 12140757
    [Abstract] [Full Text] [Related]

  • 17. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.
    Church DR, Lee E, Thompson TA, Basu HS, Ripple MO, Ariazi EA, Wilding G.
    Prostate; 2005 May 01; 63(2):155-68. PubMed ID: 15486991
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF.
    Clin Cancer Res; 2000 Mar 01; 6(3):901-8. PubMed ID: 10741714
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M, Asim M, Eskelinen H, Linke T, Baniahmad A.
    J Mol Endocrinol; 2009 May 01; 42(5):429-35. PubMed ID: 19223455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 88.